Breaking News, Collaborations & Alliances

XORTX Selects Altasciences to Conduct Pharmacokinetic Bridging Study

Will support the development of new therapies for progressive kidney disease and acute kidney injury.

Author Image

By: Charlie Sternberg

Associate Editor

Altasciences has been chosen by XORTX Therapeutics Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19.   XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order to slow the progression of the genetic disorder ADPKD, and protect against acute kidney injury following COVID-19 infection. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters